KR101419327B1 - 항바이러스 화합물 및 방법 - Google Patents

항바이러스 화합물 및 방법 Download PDF

Info

Publication number
KR101419327B1
KR101419327B1 KR1020087001886A KR20087001886A KR101419327B1 KR 101419327 B1 KR101419327 B1 KR 101419327B1 KR 1020087001886 A KR1020087001886 A KR 1020087001886A KR 20087001886 A KR20087001886 A KR 20087001886A KR 101419327 B1 KR101419327 B1 KR 101419327B1
Authority
KR
South Korea
Prior art keywords
virus
compound
guanidine
naphthoyl
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020087001886A
Other languages
English (en)
Korean (ko)
Other versions
KR20080021810A (ko
Inventor
게리 디닌 이워트
웨인 모리스 베스트
Original Assignee
바이오트론 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005903360A external-priority patent/AU2005903360A0/en
Application filed by 바이오트론 리미티드 filed Critical 바이오트론 리미티드
Publication of KR20080021810A publication Critical patent/KR20080021810A/ko
Application granted granted Critical
Publication of KR101419327B1 publication Critical patent/KR101419327B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020087001886A 2005-06-24 2006-06-23 항바이러스 화합물 및 방법 Active KR101419327B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2005903360A AU2005903360A0 (en) 2005-06-24 Anti-viral compounds and methods
AU2005903360 2005-06-24
PCT/AU2006/000880 WO2006135978A1 (en) 2005-06-24 2006-06-23 Antiviral compounds and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020147010199A Division KR20140072101A (ko) 2005-06-24 2006-06-23 항바이러스 화합물 및 방법

Publications (2)

Publication Number Publication Date
KR20080021810A KR20080021810A (ko) 2008-03-07
KR101419327B1 true KR101419327B1 (ko) 2014-07-14

Family

ID=37570036

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087001886A Active KR101419327B1 (ko) 2005-06-24 2006-06-23 항바이러스 화합물 및 방법
KR1020147010199A Ceased KR20140072101A (ko) 2005-06-24 2006-06-23 항바이러스 화합물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147010199A Ceased KR20140072101A (ko) 2005-06-24 2006-06-23 항바이러스 화합물 및 방법

Country Status (16)

Country Link
US (3) US8669280B2 (https=)
EP (2) EP2826770B1 (https=)
JP (2) JP5373392B2 (https=)
KR (2) KR101419327B1 (https=)
CN (2) CN103274970B (https=)
AU (1) AU2006261593B2 (https=)
BR (2) BRPI0612309B8 (https=)
CA (1) CA2612403C (https=)
DK (2) DK1902017T3 (https=)
ES (2) ES2710662T3 (https=)
NZ (3) NZ564398A (https=)
PL (2) PL1902017T3 (https=)
PT (2) PT2826770T (https=)
SG (1) SG163517A1 (https=)
WO (1) WO2006135978A1 (https=)
ZA (1) ZA200800256B (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5030587B2 (ja) * 2003-06-26 2012-09-19 バイオトロン・リミテッド 抗ウイルスアシルグアニジン化合物および方法
EP2826770B1 (en) * 2005-06-24 2018-09-12 Biotron Limited Acylguanidine compounds with antiviral activity
CA2688194A1 (en) 2007-05-23 2008-12-04 Siga Technologies, Inc. Antiviral drugs for treatment or prevention of dengue infection
US20100254942A1 (en) * 2007-08-03 2010-10-07 Biotron Limited Hepatitis c antiviral compositions and methods
AU2013219202B2 (en) * 2007-08-03 2016-12-08 Biotron Limited Hepatitis C antiviral compositions and methods
JP5569857B2 (ja) * 2007-08-10 2014-08-13 アステラス製薬株式会社 二環式アシルグアニジン誘導体
US20110306621A1 (en) * 2009-02-09 2011-12-15 Isao Kinoyama Acylguanidine derivatives
EP2394988A4 (en) * 2009-02-09 2012-09-05 Astellas Pharma Inc SUBSTITUTED ACYLGUANIDINE DERIVATIVE
TW201116281A (en) 2009-08-06 2011-05-16 Astellas Pharma Inc N atom containing ring acylguanidine derivatives
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
US9126106B1 (en) 2010-11-05 2015-09-08 Wms Gaming, Inc. Promotional content coordination in wagering game machines
JP5906253B2 (ja) * 2010-12-16 2016-04-20 アッヴィ・インコーポレイテッド 抗ウイルス性化合物
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
DK3785717T3 (da) 2015-09-16 2022-03-21 Gilead Sciences Inc Fremgangsmåder til behandling af coronaviridae-infektioner
SG11201907034PA (en) 2017-02-08 2019-08-27 Biotron Ltd Methods of treating influenza
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
CA3059777C (en) 2017-05-01 2023-02-21 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
AU2020390851A1 (en) * 2019-11-26 2022-06-09 Biotron Limited Methods of treating HIV-1 infection
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
WO2022251318A1 (en) 2021-05-26 2022-12-01 Gilead Sciences, Inc. Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
JP2024543259A (ja) * 2021-11-24 2024-11-20 バイオトロン リミティッド ＳＡＲＳ－ＣｏＶ－２感染を治療する方法
KR20240154646A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
JP2025508941A (ja) 2022-03-03 2025-04-10 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物並びにその作製及び使用方法
KR20240155326A (ko) 2022-03-03 2024-10-28 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물 및 이의 제조와 사용 방법
WO2023167055A1 (ja) * 2022-03-03 2023-09-07 日本曹達株式会社 抗ウイルス剤
US20240009220A1 (en) 2022-06-06 2024-01-11 Gilead Sciences, Inc. Methods for treatment of viral infections
WO2024006376A1 (en) 2022-06-29 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
CN115260100B (zh) * 2022-08-08 2023-12-12 赛诺瑞生物医药技术(无锡)有限公司 一种用于制备冠状病毒治疗药物的取代酰基胍类化合物和用途
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
WO2024173458A1 (en) 2023-02-16 2024-08-22 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
US20250090537A1 (en) 2023-08-31 2025-03-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
AU2024330988A1 (en) 2023-08-31 2026-02-19 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
WO2025054278A1 (en) 2023-09-06 2025-03-13 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US20250109157A1 (en) 2023-09-28 2025-04-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4251545A (en) * 1979-09-19 1981-02-17 Gaf Corporation Fungicidal process using 1-(alkoxyaroyl)guanidines
JPH08225513A (ja) * 1994-12-21 1996-09-03 Kanebo Ltd ナフトイルグアニジン誘導体
JPH1081664A (ja) * 1996-05-29 1998-03-31 Hoechst Ag 置換された２−ナフトイルグアニジン、その製法、医薬または診断剤としてのその使用およびそれを含有する医薬
JP2000506515A (ja) * 1996-02-12 2000-05-30 シェリング アクチェンゲゼルシャフト 抗菌及び／又は抗ウイルス作用を有する避妊薬放出システム

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2734904A (en) * 1956-02-14 Xcxnhxc-nh
US4544670A (en) * 1982-08-24 1985-10-01 William H. Rorer, Inc. Method of treating coccidiosis with acyl guanidines
JPH0218632A (ja) 1988-07-07 1990-01-22 Matsushita Electric Ind Co Ltd 論理ゲート評価装置と論理ゲート評価方法
DE3929582A1 (de) 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE4328869A1 (de) 1993-08-27 1995-03-02 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4421536A1 (de) 1994-06-20 1995-12-21 Hoechst Ag Perfluoralkylgruppen tragende phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19518796A1 (de) 1995-05-22 1996-11-28 Hoechst Ag Fluorphenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19527305A1 (de) 1995-07-26 1997-01-30 Hoechst Ag Substituierte Zimtsäureguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AUPO545297A0 (en) * 1997-03-04 1997-03-27 Fujisawa Pharmaceutical Co., Ltd. Guanidine derivatives
US20030113352A1 (en) 2001-12-14 2003-06-19 The Regents Of The University Of California Neutralization of stratum corneum to treat hyperkeratotic skin lesions
US20060034941A1 (en) 2002-12-23 2006-02-16 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
US20060229346A1 (en) * 2003-03-31 2006-10-12 Sucampo Ag Method for treating vascular hyperpermeable disease
JP5030587B2 (ja) 2003-06-26 2012-09-19 バイオトロン・リミテッド 抗ウイルスアシルグアニジン化合物および方法
US20070099968A1 (en) 2004-06-26 2007-05-03 Biotron Limited Antiviral compounds and methods
EP2826770B1 (en) * 2005-06-24 2018-09-12 Biotron Limited Acylguanidine compounds with antiviral activity
CA2625039A1 (en) * 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors
JP5727842B2 (ja) 2011-04-12 2015-06-03 日野自動車株式会社 車両のインストルメントパネル構造
KR101331921B1 (ko) * 2013-01-16 2013-11-21 에스케이플래닛 주식회사 영유아의 안전을 위한 스마트 인터랙션 서비스를 제공하는 장치 및 방법, 이를 이용한 시스템

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4251545A (en) * 1979-09-19 1981-02-17 Gaf Corporation Fungicidal process using 1-(alkoxyaroyl)guanidines
JPH08225513A (ja) * 1994-12-21 1996-09-03 Kanebo Ltd ナフトイルグアニジン誘導体
JP2000506515A (ja) * 1996-02-12 2000-05-30 シェリング アクチェンゲゼルシャフト 抗菌及び／又は抗ウイルス作用を有する避妊薬放出システム
JPH1081664A (ja) * 1996-05-29 1998-03-31 Hoechst Ag 置換された２−ナフトイルグアニジン、その製法、医薬または診断剤としてのその使用およびそれを含有する医薬

Also Published As

Publication number Publication date
US20090099239A1 (en) 2009-04-16
BR122020006906B8 (pt) 2021-07-27
CN103274970A (zh) 2013-09-04
EP1902017B1 (en) 2014-03-26
CN103274970B (zh) 2015-02-25
JP5616410B2 (ja) 2014-10-29
NZ610715A (en) 2014-07-25
US8669280B2 (en) 2014-03-11
EP2826770A1 (en) 2015-01-21
DK2826770T3 (en) 2019-01-07
EP1902017A1 (en) 2008-03-26
WO2006135978A1 (en) 2006-12-28
US20160376231A1 (en) 2016-12-29
ES2491217T3 (es) 2014-09-05
DK1902017T3 (da) 2014-06-30
EP2826770B1 (en) 2018-09-12
JP5373392B2 (ja) 2013-12-18
BRPI0612309B8 (pt) 2021-05-25
PL2826770T3 (pl) 2019-02-28
NZ596107A (en) 2013-09-27
US10683263B2 (en) 2020-06-16
JP2013049676A (ja) 2013-03-14
KR20080021810A (ko) 2008-03-07
HK1206330A1 (en) 2016-01-08
AU2006261593B2 (en) 2013-01-24
AU2006261593A1 (en) 2006-12-28
CA2612403C (en) 2014-03-25
ES2710662T3 (es) 2019-04-26
EP1902017A4 (en) 2011-12-28
SG163517A1 (en) 2010-08-30
JP2008543886A (ja) 2008-12-04
CA2612403A1 (en) 2006-12-28
CN101208297B (zh) 2013-04-24
PT2826770T (pt) 2018-12-18
US20140066487A1 (en) 2014-03-06
BRPI0612309A2 (pt) 2010-11-03
BR122020006906B1 (pt) 2021-03-16
CN101208297A (zh) 2008-06-25
HK1109615A1 (en) 2008-06-13
KR20140072101A (ko) 2014-06-12
ZA200800256B (en) 2009-08-26
NZ564398A (en) 2011-11-25
BRPI0612309B1 (pt) 2021-03-02
PL1902017T3 (pl) 2014-08-29
US9440926B2 (en) 2016-09-13
PT1902017E (pt) 2014-07-11

Similar Documents

Publication Publication Date Title
KR101419327B1 (ko) 항바이러스 화합물 및 방법
KR101558403B1 (ko) Ｃ형 간염 바이러스 조성물 및 방법
US5583131A (en) Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity
KR20170129244A (ko) 섬유증 및 섬유증 관련 질병 치료용 조성물
AU2013205388B2 (en) Antiviral compounds and methods
HK1206330B (en) Acylguanidine compounds with antiviral activity
HK1109615B (en) Antiviral acylguanidine compounds
US8309602B2 (en) Multi-substituted diarylanilines as non-nucleoside HIV reverse transcriptase inhibitors, and preparation and use thereof
AU2013219202B2 (en) Hepatitis C antiviral compositions and methods
HK1141718B (en) Hepatitis c antiviral compositions comprising 5-(1-methylpyrazol-4-yl)2-naphthoylguanidine and 2'-c-methyladenosine or 2'-c-methylcytidine
HK1014368B (en) Linked cyclic polyamines with activity against hiv

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080124

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110620

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130326

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20131217

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130326

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20140317

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20131217

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2014101001598

Request date: 20140317

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140416

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20140317

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20140317

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20130826

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20140507

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20140425

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20140708

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20140708

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20170627

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20170627

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20190619

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20190619

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20200609

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20210629

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20220705

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20240627

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20250626

Start annual number: 12

End annual number: 12